Literature DB >> 3742487

In vivo potentiation of cis-diamminedichloroplatinum (II) antitumor activity by pretreatment with sparsomycin.

Z Zylicz, D J Wagener, H van Rennes, J M Wessels, E van der Kleijn, W J de Grip, H C Ottenheijm, L A van den Broek.   

Abstract

The influence of protein synthesis inhibition by sparsomycin (Sm) on in vivo cisplatin activity has been studied on BALBc X DBA2: F1 mice bearing L1210 leukemia i.p. Sm alone at the dose range from 0.5 to 3.0 mg/kg did not significantly improve animal survival. Sm potentiated cisplatin activity only when given 3 or 6 h prior to cisplatin (P less than 0.001). Sm 0.5-1.5 mg/kg 3 h prior to cisplatin resulted in a significant prolongation of animal survival (P less than 0.001) and 66% cures in each group versus 0% due to cisplatin alone. Sm pretreatment decreased weight loss due to cisplatin suggesting that it probably is able to decrease cisplatin toxicity.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3742487     DOI： 10.1016/0304-3835(86)90038-8

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  4 in total

1.  Pharmacokinetics and toxicology of sparsomycin in beagle dogs.

Authors:  Z Zylicz; D J Wagener; P Fernandez del Moral; H van Rennes; J M Wessels; B Winograd; E van der Kleijn; T B Vree; U van Haelst; L A van den Broek
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  In vivo antitumor activity of sparsomycin and its analogues in eight murine tumor models.

Authors:  Z Zylicz; D J Wagener; H van Rennes; E van der Kleijn; P Lelieveld; L A van den Broek; H C Ottenheijm
Journal:  Invest New Drugs       Date:  1988-12       Impact factor: 3.850

3.  Correlation of the in vitro cytotoxicity of ethyldeshydroxysparsomycin and cisplatin with the in vivo antitumour activity in murine L1210 leukaemia and two resistant L1210 subclones.

Authors:  H P Hofs; D J Wagener; V de Valk-Bakker; H van Rennes; A J van Zeist; L A van den Broek; H C Ottenheijm
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Preclinical antitumor activity of ethyldeshydroxysparsomycin in combination with cisplatin.

Authors:  H P Hofs; D J Wagener; V De Valk-Bakker; H Van Rennes; D De Vos; W H Doesburg; H C Ottenheijm; W J De Grip
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.